Trials / Completed
CompletedNCT00871182
Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
A Randomized, Double-blind, Single Dose, Four-period, Six-treatment, Placebo-controlled, Balanced, Incomplete Block, Cross-over, Study of Four Doses of Inhaled PT001 in Patients With Mild to Moderate COPD, Compared to Open Label Tiotropium
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Pearl Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 40 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of inhaled PT001 compared to placebo and tiotropium in patients with mild to moderate chronic obstructive pulmonary disease (COPD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Inhaled PT001 | single dose, inhaled |
| DRUG | Inhaled Placebo | single dose, inhaled |
| DRUG | Tiotropium Handihaler | single dose, tiotropium 18 mcg administered via the Handihaler |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2009-09-01
- Completion
- 2009-09-01
- First posted
- 2009-03-30
- Last updated
- 2013-06-21
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00871182. Inclusion in this directory is not an endorsement.